Focused On-demand Library for Queuine tRNA-ribosyltransferase catalytic subunit 1

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our top-notch dedicated system is used to design specialised libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

Q9BXR0

UPID:

TGT_HUMAN

Alternative names:

Guanine insertion enzyme; tRNA-guanine transglycosylase

Alternative UPACC:

Q9BXR0; B4DFM7; Q96BQ4; Q9BXQ9

Background:

Queuine tRNA-ribosyltransferase catalytic subunit 1, also known as Guanine insertion enzyme or tRNA-guanine transglycosylase, plays a pivotal role in the modification of tRNA. It catalyzes the replacement of guanine with queuine at the wobble position of tRNA, facilitating the production of the hypermodified nucleoside queuosine. This enzymatic action is crucial for the accurate translation of genetic information into proteins.

Therapeutic significance:

Understanding the role of Queuine tRNA-ribosyltransferase catalytic subunit 1 could open doors to potential therapeutic strategies. Its involvement in the fundamental process of protein synthesis highlights its potential as a target for drug discovery, aiming to modulate protein production in various diseases.